Can-Fite BioPharma Ltd. cotiza a 1.95 USD y tiene una capitalización bursátil de $6M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical …
| Periodo | 2025-08 | 2024-03 | 2023-11 | 2023-08 |
|---|---|---|---|---|
| Real | — | $-60.00 | — | — |
| Estimado | $-2.40 | $-7.40 | $-8.60 | $-14.50 |
| Sorpresa | — | -710.8% | — | — |
| Métrica | CANF | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -2456.8% | -38.6% | -2418.2% |
| Net Margin | -2426.7% | -33.6% | -2393.1% |
| FCF Margin | -2210.1% | -13.9% | -2196.3% |
| ROE | -175.8% | -40.4% | -135.3% |
| ROA | -103.3% | -32.0% | -71.3% |
| Current Ratio | 3.46 | 2.84 | +0.62 |
| Debt / Equity | — | 0.28 | — |